Baillie Gifford & CO Recursion Pharmaceuticals, Inc. Put Options Transaction History
Baillie Gifford & CO
- $126 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RXRX
# of Institutions
290Shares Held
241MCall Options Held
984KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$207 Million2.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$136 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$109 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$97.2 Million1.74% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V711.9MShares$75.2 Million100.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.14B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...